LOS ANGELES and TOKYO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Science 37, the Operating System for today’s more agile clinical...
– Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders –MIAMI BEACH, Fla., Oct....
Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Estrogen Receptor Antagonist to Determine Potential of Complete Hormone Blockade on...
Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy...
Posters Detail Preclinical Data on the Company’s WTX-124 and WTX-330 Molecules for the Potential Treatment of CancerCAMBRIDGE, Mass., Oct. 27,...
TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) is pleased to announce a...
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the...
Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION,...
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be...
BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call...
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based...
Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade...
NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
Emerging Sexual Health Wellness Brand Launches BLOOM™ (a Female Arousal Gel) and AURALIEF™ (a Cannabis-Infused Sublingual Strip)VANCOUVER, BC CANADA, Oct....
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at...
New Members Add Depth to Board with Experience in Strategic Transactions, Strategy and Commercial Planning, and GovernanceMIRAMAR, Fla., Oct. 27,...
Mean IRAK4 degradation of up to 96% in PBMC and up to 97% inhibition of ex vivo induction of multiple...
WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore,...
